MBX Biosciences, Inc. (MBX) stock
MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$53.10−0.02 (-0.04%)
Close on Nov 17, 2026Market cap $2.56BP/E –Yield –
MBX Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
MBX Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$160.33M. For fiscal 2025 it was -$98.06M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$98.06M | – |
| FY2024 | Dec 31, 2024 | -$68.19M | – |
| FY2023 | Dec 31, 2023 | -$35.31M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$66.34M | – |
| Q2 FY2026 | Jun 30, 2026 | -$40.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$25.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$23.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.66M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.31M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.99M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.95M | – |
See a number that looks wrong?